ADALIMUMAB
Drug
Sandoz Inc.
Total Payments
$73,041
Transactions
10
Doctors
8
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $500.00 | 1 | 0 |
| 2017 | $72,541 | 9 | 8 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $73,041 | 10 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO DEMONSTRATE EQUIVALENT EFFICACY AND TO COMPARE SAFETY AND IMMUNOGENICITY OF A BIOSIMILAR ADALIMUMAB (GP2017) AND HUMIRA? IN PATIENTS WITH MODERATE TO SEVERE CHRONIC PLAQUE-TYPE PSORIASIS | Sandoz Inc. | $71,274 | 8 |
| A RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO DEMONSTRATE EQUIVALENT EFFICACY AND TO COMPARE SAFETY AND IMMUNOGENICITY OF A BIOSIMILAR ADALIMUMAB (GP2017) AND HUMIRA IN PATIENTS WITH MODERATE TO SEVERE CHRONIC PLAQUE-TYPE PSORIASIS | Sandoz Inc. | $1,768 | 1 |
Top Doctors Receiving Payments for ADALIMUMAB
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | General Practice | Homestead, FL | $32,746 | 1 |
| , MD | Dermatology | Beverly Hills, CA | $14,619 | 1 |
| , MD | Gastroenterology | Ventura, CA | $12,147 | 2 |
| , MD | Urology | Brooklyn, NY | $10,380 | 1 |
| , M.D | Dermatology | Webster, TX | $1,000 | 1 |
| , M.D | MOHS-Micrographic Surgery | Ocala, FL | $650.00 | 1 |
| , MD | Internal Medicine | Cypress, CA | $500.00 | 1 |
| , MD | Dermatology | Winston Salem, NC | $500.00 | 1 |
| Unknown | — | Evansville, IN | $500.00 | 1 |
Ad
Manufacturing Companies
- Sandoz Inc. $73,041
Product Information
- Type Drug
- Total Payments $73,041
- Total Doctors 8
- Transactions 10
About ADALIMUMAB
ADALIMUMAB is a drug associated with $73,041 in payments to 8 healthcare providers, recorded across 10 transactions in the CMS Open Payments database. The primary manufacturer is Sandoz Inc..
Payment data is available from 2017 to 2018. In 2018, $500.00 was paid across 1 transactions to 0 doctors.
The most common payment nature for ADALIMUMAB is "Unspecified" ($73,041, 100.0% of total).
ADALIMUMAB is associated with 2 research studies, including "A RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO DEMONSTRATE EQUIVALENT EFFICACY AND TO COMPARE SAFETY AND IMMUNOGENICITY OF A BIOSIMILAR ADALIMUMAB (GP2017) AND HUMIRA? IN PATIENTS WITH MODERATE TO SEVERE CHRONIC PLAQUE-TYPE PSORIASIS" ($71,274).